Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 59.72% is in line with its 5-year average of 60.77%, around the middle of its 5-year range (50.03%–80.59%).
0.26% below its 12-month average of 59.88%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 57.31%.
GROSS MARGIN
59.72%
GROSS MARGIN AVG TTM
59.88%
GROSS MARGIN AVG 3Y
57.07%
GROSS MARGIN AVG 5Y
60.77%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.26%
CURRENT VS 3Y AVG
+4.64%
CURRENT VS 5Y AVG
-1.72%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+44.93%
vs the sector median at left
Vivos Therapeutics, Inc.
Market Cap
$2.14M
Gross Margin
59.72%
TTM Avg
59.88%
3Y Avg
57.07%
5Y Avg
60.77%
Market Cap
$2.13M
Gross Margin
-628.02%
TTM Avg
-265.21%
3Y Avg
-2905.33%
5Y Avg
-2576.02%
Market Cap
$2.32M
Gross Margin
63.43%
TTM Avg
61.72%
3Y Avg
62.82%
5Y Avg
60.98%
Market Cap
$2.37M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.37M
Gross Margin
80.40%
TTM Avg
59.71%
3Y Avg
-452.13%
5Y Avg
-301.42%
Market Cap
$2.38M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.38M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.88M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.88M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vivos Therapeutics, Inc. (VVOS) | $2.14M | 59.72% | 59.88% | 57.07% | 60.77% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.13M | -628.02% | -265.21% | -2905.33% | -2576.02% |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | 63.43% | 61.72% | 62.82% | 60.98% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.37M | 0.00% | 0.00% | 0.00% | 0.00% |
| Onconetix, Inc. (ONCO)vs › | $2.37M | 80.40% | 59.71% | -452.13% | -301.42% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.38M | 0.00% | 0.00% | 0.00% | 0.00% |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.38M | 0.00% | 0.00% | 0.00% | 0.00% |
| Autonomix Medical, Inc. (AMIX)vs › | $1.88M | 0.00% | 0.00% | 0.00% | 0.00% |
| TransCode Therapeutics, Inc. (RNAZ)vs › | $1.88M | 0.00% | 0.00% | 0.00% | 0.00% |
| Tenon Medical, Inc. (TNON)vs › | $1.84M | 66.25% | 56.00% | 15.40% | 30.93% |
Gross Margin
59.7%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 57.31% |
| 2026-03-31 | 50.67% |
| 2025-12-31 | 78.14% |
| 2025-09-30 | 58.04% |
| 2025-06-30 | 55.24% |
| 2025-03-31 | 50.03% |
| 2024-12-31 | 56.71% |
| 2024-09-30 | 60.47% |
| 2024-06-30 | 65.39% |
| 2024-03-31 | 56.65% |
| 2023-12-31 | 59.67% |
| 2023-09-30 | 52.92% |
| 2023-06-30 | 61.80% |
| 2023-03-31 | 60.59% |
| 2022-12-31 | 60.35% |
| 2022-09-30 | 58.78% |
| 2022-06-30 | 61.85% |
| 2022-03-31 | 70.01% |
| 2021-12-31 | 70.71% |
| 2021-09-30 | 70.02% |
| 2021-06-30 | 80.59% |
| 2021-03-31 | 78.02% |
| 2020-12-31 | 81.28% |
| 2020-09-30 | 78.45% |
| 2020-06-30 | 83.34% |
| 2020-03-31 | 75.58% |
| 2019-12-31 | 71.69% |
| 2019-09-30 | 77.34% |
| 2019-06-30 | 77.70% |
| 2019-03-31 | 77.70% |
